Immuneering Corporation (IMRX) reported encouraging early data from a small phase 2a trial of its MEK inhibitor atebimetinib in frontline metastatic pancreatic cancer, showing a 12-month overall survival rate of 64%. This result compares favorably to historical data and competitors like Revolution Medicines, though the small trial size suggests caution. IMRX holds over $200 million in cash, supporting operations into 2029, but future trial expenses could reduce this runway. With a $300 million market cap and upcoming data releases at ASCO, IMRX presents a high-risk, high-reward opportunity for long-term investors as it advances toward pivotal trials.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
Fundstrat's Granny Shot US-Small & Mid-Cap ETF (GRNJ) has delivered strong year-to-date returns, beating similar ETFs like VOT and VOO despite its higher 0.75% expense ratio. The fund targets stocks at the intersection of major secular trends, partic...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
